H3L envelope protein immunization methods and H3L envelope passive protection methods
First Claim
1. A method for providing a subject with protection against poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of an antibody that binds to H3L envelope protein or an H3L envelope protein homolog to provide the subject with protection against poxvirus infection or pathogenesis, wherein the composition administered excludes an antibody that binds to vaccinia protein A33R or A33R homolog and excludes an antibody that binds to vaccinia protein L1R or L1R homolog.
6 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to, among other things, methods of protecting against poxvirus infection or pathogenesis and including pox viruses such as small pox (variola major and variola minor), cowpox, monkey pox vaccinia virus, and Molluscum Contagiosum using compositions such as human, humanized and chimeric antibodies that specifically bind to H3L protein.
47 Citations
69 Claims
- 1. A method for providing a subject with protection against poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of an antibody that binds to H3L envelope protein or an H3L envelope protein homolog to provide the subject with protection against poxvirus infection or pathogenesis, wherein the composition administered excludes an antibody that binds to vaccinia protein A33R or A33R homolog and excludes an antibody that binds to vaccinia protein L1R or L1R homolog.
-
2. A method for protecting a subject from poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of antibody that binds to H3L envelope protein or an H3L envelope protein homolog to the subject, wherein the composition administered excludes an antibody that binds to vaccinia protein A33R or A33R homolog and excludes an antibody that binds to vaccinia protein L1R or L1R homolog, and wherein the composition is administered concurrently with or following a poxvirus infection, contact with or exposure to a poxvirus, or vaccination with a poxvirus.
- 3. A method for decreasing susceptibility of a subject to a poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of an antibody that binds to H3L envelope protein or an H3L envelope protein homolog to decrease susceptibility of the subject to poxvirus infection or pathogenesis, wherein the composition administered excludes an antibody that binds to vaccinia protein A33R or A33R homolog and excludes an antibody that binds to vaccinia protein L1R or L1R homolog.
- 38. A method for providing a subject with protection against poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of an antibody to provide the subject with protection against poxvirus infection or pathogenesis, wherein the antibody binds to H3L envelope protein or an H3L envelope protein homolog and is not an antibody that binds to vaccinia protein B5R, L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, A2, or a B5R, L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, or A2 homolog.
-
39. A method for protecting a subject from poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of an antibody to protect the subject from poxvirus infection or pathogenesis, wherein the antibody binds to H3L envelope protein or an H3L envelope protein homolog and is not an antibody that binds to vaccinia protein B5R, L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, A2, or a B5R, L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, or A2 homolog, and wherein the composition is administered concurrently with or following a poxvirus infection, contact with or exposure to a poxvirus, or vaccination with a poxvirus.
-
40. A method for decreasing susceptibility of a subject to a poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of an antibody to decrease susceptibility of the subject to poxvirus infection or pathogenesis, wherein the antibody binds to H3L envelope protein or an H3L envelope protein homolog and is not an antibody that binds to vaccinia protein B5R, L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, A2, or a B5R, L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, or A2 homolog.
- 54. A method for providing a subject with protection against poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of an antibody to provide the subject with protection against poxvirus infection or pathogenesis, wherein the antibody is a first antibody that binds to H3L envelope protein or an H3L envelope protein homolog and a second antibody that binds to B5R protein or B5R protein homolog, and wherein the antibody is not an antibody that binds to vaccinia protein L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, A2, or a L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, or A2 homolog.
-
55. A method for protecting a subject from poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of antibody to protect the subject from poxvirus infection or pathogenesis, wherein the antibody is a first antibody that binds to H3L envelope protein or an H3L envelope protein homolog and a second antibody that binds to B5R protein or B5R protein homolog, and wherein the antibody is not an antibody that binds to vaccinia protein L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, A2, or a L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, or A2 homolog.
- 56. A method for decreasing susceptibility of a subject to a poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of antibody to decrease susceptibility of the subject to poxvirus infection or pathogenesis, wherein the antibody is a first antibody that binds to H3L envelope protein or an H3L envelope protein homolog and a second antibody that binds to B5R protein or B5R protein homolog, and wherein the antibody is not an antibody that binds to vaccinia protein L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, A2, or a L1R, D8L, A33R, A27L, A17L, L5, A21, H2, A28, A14, A56, A34, A36, or A2 homolog.
Specification